{"id":60888,"date":"2024-02-28T07:13:37","date_gmt":"2024-02-28T07:13:37","guid":{"rendered":"https:\/\/medsname.com\/dytor-injection\/"},"modified":"2026-04-30T10:23:41","modified_gmt":"2026-04-30T10:23:41","slug":"dytor-injection","status":"publish","type":"product","link":"https:\/\/medsbase.com\/el\/dytor-injection\/","title":{"rendered":"Dytor Injection"},"content":{"rendered":"

<\/p>\n

\n

Quick Answer \u2014 What is Dytor Injection?<\/h3>\n

Dytor Injection is a 2 ml ampoule containing torasemide 10 mg \u2014 a potent loop diuretic used intravenously to rapidly remove excess fluid in congestive heart failure, pulmonary oedema and severe oedema from liver or kidney disease. Manufactured by Cipla, it is administered by a healthcare professional and begins diuresis within 10 minutes of IV injection.<\/p>\n<\/div>\n

\n\u0391\u03c5\u03c4\u03cc \u03c0\u03bf\u03c5 \u03bb\u03b1\u03bc\u03b2\u03ac\u03bd\u03b5\u03c4\u03b5 \u03bc\u03b5 \u03c4\u03b7\u03bd MedsBase:<\/strong> \u03a0\u03b9\u03c3\u03c4\u03bf\u03c0\u03bf\u03b9\u03b7\u03bc\u03ad\u03bd\u03bf\u03c2 \u03ba\u03b1\u03c4\u03b1\u03c3\u03ba\u03b5\u03c5\u03b1\u03c3\u03c4\u03ae\u03c2 WHO-GMP \u00b7 \u0394\u03b9\u03b1\u03ba\u03c1\u03b9\u03c4\u03b9\u03ba\u03ae \u03c3\u03c5\u03c3\u03ba\u03b5\u03c5\u03b1\u03c3\u03af\u03b1 \u00b7 \u03a0\u03b1\u03b3\u03ba\u03cc\u03c3\u03bc\u03b9\u03b1 \u03b1\u03c0\u03bf\u03c3\u03c4\u03bf\u03bb\u03ae \u00b7 1,400+ \u03b5\u03c0\u03b1\u03bb\u03b7\u03b8\u03b5\u03c5\u03bc\u03ad\u03bd\u03b5\u03c2 \u03ba\u03c1\u03b9\u03c4\u03b9\u03ba\u03ad\u03c2 \u03c0\u03b5\u03bb\u03b1\u03c4\u03ce\u03bd<\/a>\n<\/div>\n

\ud83d\udce6 \u039a\u03ac\u03b8\u03b5 \u03c0\u03b1\u03c1\u03b1\u03b3\u03b3\u03b5\u03bb\u03af\u03b1 \u03ba\u03b1\u03bb\u03cd\u03c0\u03c4\u03b5\u03c4\u03b1\u03b9 \u03b1\u03c0\u03cc \u03c4\u03b7\u03bd \u03a0\u03bf\u03bb\u03b9\u03c4\u03b9\u03ba\u03ae \u0395\u03b3\u03b3\u03cd\u03b7\u03c3\u03b7\u03c2 \u0395\u03c0\u03b1\u03bd\u03b1\u03c0\u03bf\u03c3\u03c4\u03bf\u03bb\u03ae\u03c2<\/strong><\/a> \u2014 \u03b5\u03ac\u03bd \u03c4\u03bf \u03b4\u03ad\u03bc\u03b1 \u03c3\u03b1\u03c2 \u03b4\u03b5\u03bd \u03c6\u03c4\u03ac\u03c3\u03b5\u03b9 \u03b5\u03bd\u03c4\u03cc\u03c2 20 \u03b5\u03c1\u03b3\u03ac\u03c3\u03b9\u03bc\u03c9\u03bd \u03b7\u03bc\u03b5\u03c1\u03ce\u03bd, \u03c4\u03bf \u03b5\u03c0\u03b1\u03bd\u03b1\u03c0\u03bf\u03c3\u03c4\u03ad\u03bb\u03bb\u03bf\u03c5\u03bc\u03b5.<\/p>\n

\u0393\u03b9\u03b1\u03c4\u03af \u03bd\u03b1 \u03c0\u03b1\u03c1\u03b1\u03b3\u03b3\u03b5\u03af\u03bb\u03b5\u03c4\u03b5 \u03b1\u03c0\u03cc \u03c4\u03b7 MedsBase<\/h3>\n

\u03a4\u03b1 \u03b3\u03b5\u03bd\u03cc\u03c3\u03b7\u03bc\u03b1 \u03c6\u03ac\u03c1\u03bc\u03b1\u03ba\u03ac \u03bc\u03b1\u03c2 \u03c0\u03c1\u03bf\u03ad\u03c1\u03c7\u03bf\u03bd\u03c4\u03b1\u03b9 \u03b1\u03c0\u03cc \u03ba\u03b1\u03c4\u03b1\u03c3\u03ba\u03b5\u03c5\u03b1\u03c3\u03c4\u03ad\u03c2 \u03c0\u03bf\u03c5 \u03c0\u03b9\u03c3\u03c4\u03bf\u03c0\u03bf\u03b9\u03bf\u03cd\u03bd\u03c4\u03b1\u03b9 \u03b1\u03c0\u03cc \u03c4\u03b7\u03bd WHO-GMP \u03ba\u03b1\u03b9 \u03b1\u03c0\u03bf\u03c3\u03c4\u03ad\u03bb\u03bb\u03bf\u03bd\u03c4\u03b1\u03b9 \u03c0\u03b1\u03b3\u03ba\u03bf\u03c3\u03bc\u03af\u03c9\u03c2 \u03c3\u03b5 \u03b4\u03b9\u03b1\u03ba\u03c1\u03b9\u03c4\u03b9\u03ba\u03ae, \u03b1\u03c0\u03bb\u03ae \u03c3\u03c5\u03c3\u03ba\u03b5\u03c5\u03b1\u03c3\u03af\u03b1 \u2014 \u03c7\u03c9\u03c1\u03af\u03c2 \u03cc\u03bd\u03bf\u03bc\u03b1 \u03c6\u03b1\u03c1\u03bc\u03ac\u03ba\u03bf\u03c5 \u03c3\u03c4\u03bf \u03b5\u03be\u03c9\u03c4\u03b5\u03c1\u03b9\u03ba\u03cc \u03c4\u03bf\u03c5 \u03b4\u03ad\u03bc\u03b1\u03c4\u03bf\u03c2. \u039f\u03b9 \u03c0\u03bb\u03b7\u03c1\u03c9\u03bc\u03ad\u03c2 \u03bc\u03b5 \u03ba\u03ac\u03c1\u03c4\u03b1 \u03b4\u03c1\u03bf\u03bc\u03bf\u03bb\u03bf\u03b3\u03bf\u03cd\u03bd\u03c4\u03b1\u03b9 \u03bc\u03ad\u03c3\u03c9 \u03c1\u03c5\u03b8\u03bc\u03b9\u03c3\u03bc\u03ad\u03bd\u03bf\u03c5 \u03b5\u03c0\u03b5\u03be\u03b5\u03c1\u03b3\u03b1\u03c3\u03c4\u03ae (\u03bf\u03b9 \u03c0\u03b5\u03c1\u03b9\u03b3\u03c1\u03b1\u03c6\u03ad\u03c2 \u03b5\u03ba\u03ba\u03b1\u03b8\u03ac\u03c1\u03b9\u03c3\u03b7\u03c2 \u03c0\u03b5\u03c1\u03b9\u03bb\u03b1\u03bc\u03b2\u03ac\u03bd\u03bf\u03c5\u03bd \u03c1\u03c5\u03b8\u03bc\u03b9\u03c3\u03bc\u03ad\u03bd\u03bf \u03b5\u03c0\u03b5\u03be\u03b5\u03c1\u03b3\u03b1\u03c3\u03c4\u03ae \u03c0\u03bb\u03b7\u03c1\u03c9\u03bc\u03ce\u03bd \u03bc\u03b5 \u03ba\u03ac\u03c1\u03c4\u03b1 \u2014 \u03c0\u03bf\u03c4\u03ad \u201cMedsBase\u201d \u03ae \u03bf\u03c0\u03bf\u03b9\u03bf\u03b4\u03ae\u03c0\u03bf\u03c4\u03b5 \u03cc\u03bd\u03bf\u03bc\u03b1 \u03c6\u03b1\u03c1\u03bc\u03ac\u03ba\u03bf\u03c5). \u0393\u03af\u03bd\u03bf\u03bd\u03c4\u03b1\u03b9 \u03b4\u03b5\u03ba\u03c4\u03ad\u03c2 \u03ba\u03b1\u03b9 \u03c0\u03bb\u03b7\u03c1\u03c9\u03bc\u03ad\u03c2 \u03bc\u03b5 \u03ba\u03c1\u03c5\u03c0\u03c4\u03bf\u03bd\u03bf\u03bc\u03af\u03c3\u03bc\u03b1\u03c4\u03b1 \u03ba\u03b1\u03b9 \u03c4\u03c1\u03b1\u03c0\u03b5\u03b6\u03b9\u03ba\u03ae \u03bc\u03b5\u03c4\u03b1\u03c6\u03bf\u03c1\u03ac SEPA. \u039a\u03ac\u03b8\u03b5 \u03c0\u03b1\u03c1\u03b1\u03b3\u03b3\u03b5\u03bb\u03af\u03b1 \u03ba\u03b1\u03bb\u03cd\u03c0\u03c4\u03b5\u03c4\u03b1\u03b9 \u03b1\u03c0\u03cc \u03c4\u03b7\u03bd \u03a0\u03bf\u03bb\u03b9\u03c4\u03b9\u03ba\u03ae \u0395\u03c0\u03b1\u03bd\u03b1\u03c0\u03bf\u03c3\u03c4\u03bf\u03bb\u03ae\u03c2 \u0395\u03be\u03b1\u03c3\u03c6\u03b1\u03bb\u03af\u03c3\u03b5\u03ce\u03c2 \u03bc\u03b1\u03c2.<\/p>\n

What Is Dytor Injection?<\/h2>\n

Dytor Injection is a sterile solution of torasemide 10 mg per 2 ml ampoule<\/strong>, intended for intravenous or intramuscular administration. Torasemide is a potent loop diuretic of the pyridine-sulfonylurea class, closely related to furosemide but with a longer duration of action and more predictable oral bioavailability. Manufactured by Cipla Ltd in India, Dytor is a widely prescribed injectable diuretic in cardiac care units and emergency departments.<\/p>\n

The injection provides rapid diuresis \u2014 onset within 10 minutes of IV administration \u2014 which makes it the treatment of choice for acute pulmonary oedema and decompensated heart failure where rapid fluid removal is clinically critical. Compared with furosemide, torasemide has better oral-to-IV conversion consistency (approximately 1:1), so patients can be transitioned to oral therapy without dose adjustment.<\/p>\n

Uses of Dytor Injection<\/h2>\n
    \n
  • Acute decompensated heart failure<\/strong> \u2014 rapid relief of pulmonary congestion and peripheral oedema.<\/li>\n
  • Acute pulmonary oedema<\/strong> \u2014 life-threatening fluid accumulation in the lungs.<\/li>\n
  • Chronic heart failure<\/strong> \u2014 during episodes where oral diuretic absorption is impaired by gut oedema.<\/li>\n
  • Severe oedema from hepatic cirrhosis<\/strong> \u2014 when ascites and lower limb oedema are refractory to oral therapy.<\/li>\n
  • Renal oedema<\/strong> \u2014 in chronic kidney disease where loop diuretics remain effective even at reduced glomerular filtration.<\/li>\n
  • Hypertensive emergencies with fluid overload<\/strong> \u2014 as adjunctive therapy to acute blood pressure lowering.<\/li>\n<\/ul>\n

    How Dytor Works<\/h2>\n

    How Dytor Works<\/h2>\n

    Torasemide acts on the thick ascending limb of the loop of Henle<\/strong> in the kidney, where it inhibits the sodium-potassium-chloride cotransporter (Na\u207a\/K\u207a\/2Cl\u207b symporter, NKCC2). By blocking reabsorption of sodium and chloride from the tubular fluid, it causes large volumes of water to remain in the urine rather than being reabsorbed into the bloodstream. The result is rapid, potent diuresis that reduces circulating blood volume, pulmonary capillary pressure and tissue oedema.<\/p>\n

    Torasemide differs from furosemide in two important ways: it has a longer half-life (3\u20134 hours versus 1\u20132 hours for furosemide), producing a smoother, more sustained diuretic effect; and it has additional weak anti-aldosterone activity, reducing the degree of potassium loss for equivalent diuretic output.<\/p>\n

    \u0394\u03bf\u03c3\u03bf\u03bb\u03bf\u03b3\u03af\u03b1 \u03ba\u03b1\u03b9 \u03a7\u03bf\u03c1\u03ae\u03b3\u03b7\u03c3\u03b7<\/h2>\n

    Dytor Injection dosage is individualised based on clinical response:<\/p>\n\n\n\n\n\n\n
    \u0395\u03bd\u03b4\u03b5\u03af\u03be\u03b5\u03b9\u03c2<\/th>\nTypical dose<\/th>\n<\/tr>\n
    Acute heart failure<\/td>\n10\u201320 mg IV; may repeat or titrate every 2 hours based on response<\/td>\n<\/tr>\n
    Pulmonary oedema<\/td>\n20 mg IV initially, up to 200 mg\/24 h in severe cases<\/td>\n<\/tr>\n
    Hepatic \/ renal oedema<\/td>\n10\u201320 mg IV once or twice daily<\/td>\n<\/tr>\n
    Oral transition<\/td>\nSwitch to oral torasemide at equivalent daily dose once stable<\/td>\n<\/tr>\n<\/table>\n

    How to Use Dytor Injection<\/h2>\n

    Dytor is given by a qualified healthcare provider, typically in a hospital setting with continuous monitoring of blood pressure, urine output and electrolytes. For IV administration, the solution is given as a slow bolus over 2 minutes or as a continuous infusion diluted in compatible fluid. IM administration is reserved for patients without IV access. Fluid balance, renal function, and serum potassium should be checked within 24\u201348 hours of starting therapy.<\/p>\n

    Side Effects of Dytor Injection<\/h2>\n